+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypertension - Pipeline Review, H2 2019

  • ID: 4894267
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 699 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • A1M Pharma AB
  • Bayer AG
  • Eli Lilly and Co
  • Ionis Pharmaceuticals Inc
  • Omeros Corp
  • Sanofi
  • MORE
Hypertension - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2019, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 2, 37, 40, 27, 1, 80, 24 and 5 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 8 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • A1M Pharma AB
  • Bayer AG
  • Eli Lilly and Co
  • Ionis Pharmaceuticals Inc
  • Omeros Corp
  • Sanofi
  • MORE
Introduction
Hypertension - Overview
Hypertension - Therapeutics Development
Hypertension - Therapeutics Assessment
Hypertension - Companies Involved in Therapeutics Development
Hypertension - Drug Profiles
Hypertension - Dormant Projects
Hypertension - Discontinued Products
Hypertension - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypertension - Pipeline by A1M Pharma AB, H2 2019
Hypertension - Pipeline by Aadi Bioscience Inc, H2 2019
Hypertension - Pipeline by Abivax SA, H2 2019
Hypertension - Pipeline by Acceleron Pharma Inc, H2 2019
Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2019
Hypertension - Pipeline by Adhera Therapeutics, H2 2019
Hypertension - Pipeline by Aerogen Ltd, H2 2019
Hypertension - Pipeline by Aggamin LLC, H2 2019
Hypertension - Pipeline by AI Therapeutics, H2 2019
Hypertension - Pipeline by Ajanta Pharma Ltd, H2 2019

List of Figures
Number of Products under Development for Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • A1M Pharma AB
  • Aadi Bioscience Inc
  • Abivax SA
  • Acceleron Pharma Inc
  • Actelion Pharmaceuticals Ltd
  • Adhera Therapeutics
  • Aerogen Ltd
  • Aggamin LLC
  • AI Therapeutics
  • Ajanta Pharma Ltd
  • Alnylam Pharmaceuticals Inc
  • Altavant Sciences Inc
  • AMAG Pharmaceuticals Inc
  • AnGes Inc
  • AOBiome LLC
  • Apaxen
  • Apollo Therapeutics LLC
  • APT Therapeutics Inc
  • Aqualung Therapeutics Corp
  • Attgeno AB
  • ATXA Therapeutics Ltd
  • AVEO Oncology Inc
  • Bayer AG
  • Beijing Wehand-Bio Pharmaceutical Co Ltd
  • Bial - Portela & Ca SA
  • Biogen Inc
  • BioRestorative Therapies Inc
  • BioStem Technologies Inc
  • Boehringer Ingelheim International GmbH
  • Boryung Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings Plc
  • Camurus AB
  • Capricor Therapeutics Inc
  • CardioPharma Inc
  • Cellmid Ltd
  • Celsion Corp
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Chong Kun Dang Pharmaceutical Corp
  • Chugai Pharmaceutical Co Ltd
  • CinCor Pharma Inc
  • CJ HealthCare Corp
  • Complexa Inc
  • CSPC Pharmaceutical Group Ltd
  • Cumberland Pharmaceuticals Inc
  • D. Western Therapeutics Institute Inc
  • Daewon Pharmaceutical Co Ltd
  • Daewoong Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Denovo Biopharma LLC
  • Eldrug SA
  • Eli Lilly and Co
  • Elyson Pharmaceutical Co Ltd
  • Esperion Therapeutics Inc
  • Excubio Pharmaceuticals Inc
  • FunPep Co Ltd
  • Galectin Therapeutics Inc
  • Gemphire Therapeutics Inc
  • GenKyoTex SA
  • GenThera Inc
  • GEXVal Inc
  • Gilead Sciences Inc
  • Gmax Biopharm Ltd
  • Gossamer Bio Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • H. Lundbeck AS
  • Hanmi Pharmaceuticals Co Ltd
  • Hetero Labs Ltd
  • Himuka AM Pharma Corp
  • Idorsia Pharmaceutical Ltd
  • Innolife Co Ltd
  • Innopharmax Inc
  • Insmed Inc
  • Insys Therapeutics Inc
  • Inven2 AS
  • INVENT Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Japan Tobacco Inc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • KBP BioSciences Co Ltd
  • Kyowa Kirin Co Ltd
  • Kyung Dong Co Ltd
  • Larix Bioscience LLC
  • Lee's Pharmaceutical Holdings Ltd
  • Les Laboratoires Servier SAS
  • LG Chem Ltd
  • Liaoning Haiwang Biotechnoloty Co Ltd
  • LinXis BV
  • Liquidia Technologies Inc
  • LTT Bio-Pharma Co Ltd
  • Martin Pharmaceuticals Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Mifcare
  • Morphogen-IX Ltd
  • Nippon Shinyaku Co Ltd
  • Nissan Chemical Corp
  • Noorik Biopharmaceuticals AG
  • Northern Therapeutics Inc
  • Novartis AG
  • NuSirt Biopharma Inc
  • Omeros Corp
  • Orion Corp
  • Overseas Pharmaceuticals Ltd
  • Panorama Research Inc
  • Park Active Molecules
  • Pharming Group NV
  • Pharmosa Biopharm Inc
  • PhaseBio Pharmaceuticals Inc
  • Proteo Inc
  • Pulmokine Inc
  • Q BioMed Inc
  • QR Pharmaceuticals Ltd
  • Quantum Genomics SA
  • Radikal Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • Relypsa Inc
  • Renova Therapeutics Inc
  • Respira Therapeutics Inc
  • Resverlogix Corp
  • Reviva Pharmaceuticals Inc
  • Ridge Therapeutics LLC
  • RMJ Holdings LLC
  • Samik Pharmaceutical Co Ltd
  • Sanofi
  • Sarfez Pharmaceuticals Inc
  • Schrodinger LLC
  • Scipharm SaRL
  • Scohia Pharma Inc
  • Shanghai Pharmaceutical Co Ltd
  • Shanghai Xinyi Pharmaceutical Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • SJT Molecular Research SL
  • Sorrento Therapeutics Inc
  • Sosei Heptares
  • SteadyMed Therapeutics Inc
  • Stocosil Inc
  • Suda Pharmaceuticals Ltd
  • Sulfateq BV
  • Sun Pharma Advanced Research Company Ltd
  • Synokem Pharmaceuticals Ltd
  • Takeda Pharmaceutical Co Ltd
  • Target Medicals LLC
  • Theracos Inc
  • Theragene Pharmaceuticals Inc
  • Theravance Biopharma Inc
  • Topadur Pharma AG
  • Translate Bio Inc
  • Tritech Biopharmaceuticals Co Ltd
  • United Therapeutics Corp
  • Vascular BioSciences
  • VasThera Research Institute
  • Vectus Biosystems Ltd
  • Velocity Pharmaceutical Development LLC
  • VG Life Sciences Inc
  • Vivus Inc
  • Windtree Therapeutics Inc
  • XuanZhu Pharma Co Ltd
  • Yuhan Corp
  • Zhejiang Conba Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll